Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 1(63), 2019

DOI: 10.1128/aac.01634-18

Links

Tools

Export citation

Search in Google Scholar

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

Journal article published in 2018 by David R. Andes, Mahmoud A. Ghannoum, Pranab K. Mukherjee, Laura L. Kovanda ORCID, Qiaoyang Lu, Mark E. Jones, Anne Santerre Henriksen, Christopher Lademacher, William W. Hope ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with drug MICs of ≥16 µg/ml, but there was no relationship with clinical outcomes in cases where the MIC was <16 µg/ml for either drug.